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Abstract. Balloon angioplasty (PTA) is an established treatment
modality for stenosis in dysfunctional arteriovenous fistulae
(AVF), although most studies showing efficacy have been retro-
spective, uncontrolled, and nonrandomized. In addition, it is un-
known whether correction of stenosis not associated with signif-
icant hemodynamic, functional, and clinical abnormality may
improve survival in AVF. This study was a prospective controlled
open trial to evaluate whether prophylactic PTA of stenosis not
associated with access dysfunction improves survival in native,
virgin, radiocephalic forearm AVF. Sixty-two stenotic, function-
ing AVF, i.e., able to provide adequate dialysis, were enrolled in
the study: 30 were allocated to control and 32 to PTA. End points
of the study were either AVF thrombosis or surgical revision due
to reduction in delivered dialysis dose. Kaplan-Meier analysis
showed that PTA improved AVF functional failure-free survival
rates (P 0.012) with a fourfold increase in median survival and
a 2.87-fold decrease in risk of failure. Cox proportional hazard
model identified PTA as the only variable associated with out-
come (P 0.012). PTA induced an increase in access blood flow
rate (Qa) by 323 (236 to 445) ml/min (P 0.001), suggesting that
improved AVF survival is the result of increased Qa. PTA was
also associated with a significant decrease in access-related mor-
bidity by approximately halving the risk of hospitalization, central
venous catheterization, and thrombectomy (P 0.05). This study
shows that prophylactic PTA of stenosis in functioning forearm
AVF improves access survival and decreases access-related mor-
bidity, supporting the usefulness of preventive correction of ste-
nosis before the development of access dysfunction. It also
strongly supports surveillance program for early detection of
stenosis.
Transluminal percutaneous angioplasty (PTA) is an established
treatment modality for vascular access stenosis (1), although
most of the data showing its efficacy in extending access
survival have been obtained from either retrospective or pro-
spective nonrandomized trials with historical rather than con-
current controls. The few prospective controlled randomized
studies available report conflicting results, with improved or
unchanged patency rates after PTA in both grafts (2–5) and
arteriovenous fistulae (AVF) (6,7), and further studies of this
kind are clearly needed (8).
Due to the lack of prospective trials, it is also unknown
whether prophylactic correction of anatomic stenosis unasso-
ciated with any significant functional, hemodynamic, or clini-
cal abnormality can extend access survival, particularly in
respect to AVF, which show excellent longevity and can re-
main patent even at access blood flow rate (Qa) lower than the
prescribed blood pump flow rate (Qb) (1).
Yet prophylactic measures are currently judged to be unwar-
ranted for stenosis unassociated with a delivered dialysis dose
reduction (1), though a recent short-term preliminary prospec-
tive study suggested that PTA is more effective in improving
patency rates in AVF with subclinical (9) than in those with
clinically evident stenosis (10).
Our aim was to perform a prospective, controlled, open trial to
evaluate whether prophylactic PTA of stenosis unassociated with
impaired delivery of dialysis (i.e., in a functioning access) can
affect survival in mature, virgin (i.e., with no prior surgical or
percutaneous interventional procedure) (4), native forearm AVF.
Material and Methods
This study was a single-center pilot trial performed at the Hemo-
dialysis Unit, Ospedale Policlinico in Verona, between January 1995
and December 2001.
Study Design
Subject Eligibility. Of the 141 subjects on dialysis at the unit
during the study period, 96 had functioning, mature, virgin, native
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forearm AVF and were therefore eligible for the study. The other 45
subjects were excluded from the study either because they had a
vascular access other than mature native forearm AVF or because they
had mature forearm AVF unable to provide spKt/V  1.2 in a 4-h
dialysis session, or that were not virgin.
Subject Allocation. All eligible subjects underwent angiography
if they met the Qb, recirculation, and Qa criteria specified below.
Fistulography identified 62 AVF in 60 subjects with significant ste-
nosis (50% reduction of luminal diameter compared with an adja-
cent nonstenosed segment). All stenotic AVF were considered as
functioning because they were providing a spKt/V  1.2 in a 4-h
dialysis session (11). In the majority of AVF, the anastomosis was
located at the wrist (dAVF); whereas, in a minority, it was situated in
the mid-portion of forearm (pAVF), either electively or due to a more
peripheral AVF failing to mature.
All 62 stenotic AVF were enrolled in the study, and the first 12
subjects, enrolled in January 1995, were allocated either to the obser-
vational, no-intervention arm (Control) or to the PTA-treatment arm
(PTA), depending on their dialysis shift, by tossing a coin: five
subjects treated in the afternoon shift were assigned to Control, and
seven subjects treated in the morning shift were assigned to PTA.
Subjects were thereafter allocated to one or the other group using the
minimization technique (12,13), a method aiming to reduce the im-
balance between groups. Subjects were assigned to whichever arm
would minimize the imbalance in term of the number of AVF and the
subjects’ clinical and demographic characteristics, including age, gen-
der, prevalence of diabetes, and symptomatic cardiovascular disease
(i.e., coronary artery and/or cerebral and/or peripheral vascular dis-
ease), but irrespective of their dialysis shift.
At the end of December 2001, 30 AVF (from 30 subjects) were
assigned to the Control and 32 AVF (from 30 subjects) to PTA. None
of the subject were lost to follow-up, so all AVF were included in the
final analysis. The study was not blinded, because the identification of
thrombosis is based on objective criteria, and the adequacy of dialysis,
as an indication for surgical revision of the access, was evaluated by
the investigators. No sample power calculation was performed before
the study. All subjects gave informed consent to the protocol of the
study, which was approved by the local Ethical Committee.
Access Surveillance
Access surveillance program was based on Qb monitoring and
urea-based access recirculation (Ru) during the period between Jan-
uary 1995 and January 1998 and on Qb monitoring, ultrasound dilu-
tion recirculation (Rhd), and Qa measurements by Transonic HD01
monitor (14) from February 1998 onwards.
Qb was monitored during each dialysis session: the prescribed Qb
ranged from 300 to 350 ml/min, and Negative Arterial pre-pump
Pressure (NAP) alarm was set at 250 mmHg; any decrease in Qb
prompting continuation of dialysis due to high NAP on at least two
consecutive hemodialysis runs (dQb, ml/min) was recorded.
Qa was measured quarterly by ultrasound dilution technique with
Transonic HD01 monitor (Transonic System Inc., Ithaca, NY), as
described elsewhere (14). AVF were cannulated with 15-gauge nee-
dles, and the “arterial” needle was placed in the main trunk of the
feeding vein proximal to any collateral veins and facing the incoming
blood flow (15). Qa measurements were taken in triplicates 30 to 90
min after starting dialysis, and the measurements were then averaged.
R was evaluated with the urea-based method (Ru) using the two-
needle slow-flow technique (16) and with the ultrasound dilution
technique using the Transonic HD (Rhd). Tests were performed 30
min after starting dialysis.
For Ru measurement, arterial (A) and venous (V) samples were
draw at Qb 300 to 350 ml/min and the systemic (S) sample was drawn
from the arterial line after reducing Qb at 50 ml/min for 20 to 30 s.
BUN was measured in all samples and Ru was calculated as follows:
Ru (%)  (S  A)  (S  V)  100
Angiography was indicated where dQb 30 ml/min in at least two
consecutive hemodialysis sessions in 25 AVF, 20 of which were
evaluated before the ultrasound dilution monitoring technique became
available; Ru  5% in 4; Rhd  0 in 1; ultrasound dilution Qa  850
ml/min in 32.
Fistulography
Fistulography was performed before dialysis using the “arterial”
needle for contrast medium injection. The AVF was then visualized in
its integrity inverting the flow in the venous limb with the aid of an
inflated sphygmomanometer. On the five occasions when it was
difficult to visualize the anastomosis, the fistulogram was obtained by
puncturing the brachial artery in a dialysis-free day.
Intervention
PTA of stenotic segments was performed under light anesthesia,
puncturing the AVF by the Seldinger technique. Before angioplasty,
an intravenous dose of 5000 IU of heparin was administered. Balloons
6 to 9 mm in size were used, inflated to a pressure of 12 atmosphere
for 40 to 60 s. Lesions resistant to dilatation were sequentially
subjected to multiple dilatation up to 20 atmosphere of pressure. An
angiogram was performed immediately after PTA, and the procedure
was considered anatomically successful if less than 30% of residual
stenosis was recorded. The initial interventional procedure was always
performed within 3 wk from the diagnosis of stenosis, and no access
failed between angiography and PTA. After the initial PTA, all AVF
remained under surveillance, and fistulography was performed if they
met the previously outlined criteria. All restenoses were treated again
by PTA.
Outcome
Study end point was access functional failure, defined either as
thrombosis or surgical revision due to a decrease in spKt/V to a value
 1.0, as an indicator of inadequate dialysis delivery (17). AVF
functional survival was evaluated as the time interval from angiogra-
phy to thrombosis or surgical revision, disregarding any repeat PTA
for restenosis. Subjects were censored in the event of death or trans-
plantation or upon reaching the end of the study period with functional
AVF (18).
Statistical Analyses
Data are reported as percentage, mean  SD, or median (95%
confidence interval), as appropriate. Normally distributed data were
analyzed by Fisher exact test or nonpaired t test, skewed data by
Mann-Whitney U test. The primary outcome of the analysis was the
computation of the functional access failure-free survival rates ac-
cording to the Kaplan-Meier method (19), and survival curves were
compared using the log-rank test. In addition, Cox proportional hazard
model was used to evaluate whether subjects and AVF-related prog-
nostic features other than treatment could influence outcome (20).
Significance was set at two-sided P  0.05. Statistical analyses were
performed using the SPSS version 10.0 (SPSS Inc., Chicago, IL).
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Results
The characteristics of the subjects and AVF are reported in
Tables 1 and 2, respectively. The Control and PTA arms were
well matched for prognostic factors associated with AVF sur-
vival, including subjects age and gender, presence of diabetes
and symptomatic cardiovascular disease, age of the access,
hemodynamic status, and number, degree, length and distribu-
tion of stenoses. The median length of follow-up was also
comparable, i.e. 13.0 mo (11.9 to 23.4 mo) in Control group
and 17.5 mo (15.7 to 39.9 mo) in PTA group (P  0.075).
During the study, four subjects in the Control group died and
three were transplanted, whereas five died and five were trans-
planted in the PTA group. Kaplan-Meier analysis showed that
PTA arm had significantly higher unadjusted functional fail-
ure-free AVF survival rates than Controls (P  0.012), as
shown in Figure 1. Median AVF survival was 84.0 mo (51.8 to
116.2 mo) in the PTA group and 21.0 mo (9.8 to 32.2 mo) in
Controls (P  0.001).
Cox multivariate proportional hazard analysis identified
PTA as the only variable significantly associated with throm-
bosis or surgical revision (Exp(B)  3.28; 95% CI  1.30 to
8.27; P  0.012), while all other variables included in the
model (subjects’ age and gender, diabetes, cardiovascular dis-
ease, AVF age, and location of anastomosis) were NS.
After the initial PTA, 28 restenoses were documented in 17
AVF (restenosis rate  0.388 event/AVF  year at risk); the
median time to restenosis was 8.0 mo (6.8 to 15.0 mo). The
anatomical success rate of PTA was 93.3% and the degree of
residual stenosis was 12  13% (P  0.001). There was only
one major thrombotic complication of PTA, corresponding to a
1.7% complication rate.
PTA was associated with a significant improvement in AVF
hemodynamic status. Immediately after PTA, i.e., within a
week of the procedure, Qb returned to the prescribed level in
all AVF increasing by 29.0  35.2 ml/min, R was abolished in
the three AVF in which it had been documented, and Qa rose
significantly by a median 323 (236 to 445) ml/min (n  26,
P  0.001), as shown in Figure 2.
The effects of PTA on unadjusted vascular access–related
morbidity are shown in Table 3, the data are presented as event
per AVF per year at risk, and the relative risk is also calculated.
Sixteen AVF in the Control arm and 9 in PTA arm failed; 14
AVF thrombosed in Control and 6 in PTA; and the proportion
of thrombosed AVF differed significantly between the two
arms (P  0.029), while the proportion of AVF undergoing
elective surgery was comparable.
Sixteen Control subjects and eight PTA subjects were hos-
pitalized (P  0.036), while temporary hemodialysis central
venous catheters were needed in 11 Control and 6 PTA sub-
jects (P  0.038).
Discussion
PTA is regarded as an established treatment modality for
stenosis in vascular access for hemodialysis, although the vast
majority of trials reporting its efficacy are uncontrolled (8) and
the few available prospective randomized controlled studies
report inconsistent results. Short-term prospective randomized
Table 1. Subjects’ demographic and clinical characteristics
Control PTA
Number of patients 30 30
Age (yr) 61.5 13.4 57.3 16.7
Gender (male/female) 20/10 18/12
Prevalence of elderly
(65 yr) (%)
36.7 33.3
Prevalence of diabetes (%) 26.7 23.3
Prevalence of cardiovascular
disease (%)
33.3 40.0
sp Kt/V 1.33 0.11 1.28  0.06
Table 2. AVF Characteristics
Control PTA
Number of AVF 30 32
AVF age (mo) 15.5 (2.0 to 28.5) 10.0 (1.5 to 28.0)
AVF anastomosis location (%)
wrist (dAVF) 83.3 84.4
mid-forearm (pAVF) 16.7 15.6
Degree of stenosis (%) 71 9 76 8
Prevalence of multiple stenoses (%) 33.3 34.4
Prevalence of stenoses 3 cm (%) 10.0 7.2
Location of stenoses (%)
arterial 2.3 1.8
venous perianastomotic (initial 4 cm) 78.9 75.0
venous distal (after the initial 4 cm) 18.8 23.2
Prevalence of Ru  5% or Rhd  0 (%) 6.7 9.4
Decrease in Qb to continue dialysis (ml/min) 40 (14 to 49) 36 (15 to 41)
Access blood flow (ml/min) 473 236 (n  14) 451  168 (n  18)
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studies on AVF have produced conflicting data; the same
investigators found that PTA significantly decreased (7) or
failed to influence (6) the thrombosis rate.
Moreover, the best time for PTA has yet to be clearly
defined; while there is evidence to support elective intervention
on a malfunctioning access, correction of stenosis in the ab-
sence of significant hemodynamic, functional, or clinical im-
pairment of the access is not warranted because there are no
prospective studies to demonstrate its effectiveness (1). This
opinion may seem particularly applicable to AVF, for which
preventive PTA may prove neither beneficial nor cost-effec-
tive, given its already low failure rate.
Our findings (that prophylactic PTA reduces functional fail-
ure rates in functioning AVF) support the usefulness of PTA
for the preventive treatment of stenosis, before the onset of
significant access dysfunction, i.e. in AVF that are still func-
tioning well in spite of stenosis-induced hemodynamic
changes. PTA was associated with a fourfold increase in me-
dian functional failure-free survival and a 2.87-fold reduction
of AVF relative risk of failure, although repeated treatments
were often needed due to the high restenosis rate in most
accesses.
The exclusive role of treatment in determining functional
fistula survival is confirmed by the Cox proportional hazard
analysis, which identified PTA as the only variable associated
with AVF failure, while all other potential prognostic factors
did not influence outcome.
PTA was consistently associated with an improved AVF
hemodynamic status, because it abolished R, restored Qb to the
prescribed value, and, as reported by others (9,21–23), it pro-
duced a direct median 323 ml/min increase in Qa, which was
constant over the whole range of baseline Qa levels. In addi-
tion, post-PTA Qa levels were always higher than 300 ml/min,
a threshold below which the risk of incipient thrombosis is
reported very high (24).
These findings suggest that the improved functional survival
after a program of repeat PTA is due to the hemodynamic
effect of PTA, in line with the notion that blood flow is a
major, if not the main, determinant of patency in AVF (25).
Our data confirm that a program of repeat PTA of stenosis
is associated with negligible complication rates, demonstrating
that its implementation in functioning AVF halves vascular
access-related morbidity, providing further support for the use-
fulness of elective stenosis correction by PTA even in this type
of vascular access, which already has low failure and compli-
cation rates.
Finally, our findings provide ample justification to the im-
plementation of surveillance program aiming for the early
detection of stenosis in AVF.
We are aware that our study has some limitations, mainly the
lack of true randomization and blinding. We also recognize
Figure 1. Unadjusted functional arteriovenous fistulae (AVF) failure-
free survival rates according to Kaplan-Meier analysis in Control
(open circles, dashed line) and balloon angioplasty (PTA) (closed
triangles, solid line) groups.
Figure 2. Effect of PTA on Qa levels. Data are expressed as median
(95% CI). Pre- and post-PTA Qa values are significantly different (n
 26, P  0.001).
Table 3. Unadjusted vascular access-related morbidity
Control
(event per AVF-yr)
PTA
(event per AVF-yr)
Relative Risk
(Control/PTA)
Hospitalization (d) 1.994 0.603 1.81 (1.09 to 2.99)
AVF failure 0.363 0.111 2.87 (1.21 to 6.80)
Thrombectomy 0.317 0.074 1.84 (1.14 to 2.97)
Elective surgical revision 0.046 0.037 0.81 (0.27 to 2.46)
Central venous catheter placement 0.250 0.049 1.81 (1.14 to 2.88)
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that it does not provide a final answer to the question of the role
of preventive PTA in extending functioning AVF life span and
further, larger studies with a better design are needed.
In conclusion, our prospective, controlled study indicates
that a program of prophylactic repeat PTA for stenosis in
functioning forearm AVF is safe, it improves functional sur-
vival rates by improving the hemodynamic status of the access,
and it reduces access-related morbidity. Our findings also
suggest the utility of stenosis correction by PTA before the
onset of significant fistula dysfunction and strongly support the
use of surveillance program for the early detection of stenosis.
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